Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Alkermes Plc
(NQ:
ALKS
)
28.97
+0.60 (+2.11%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Alkermes Plc
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Where Alkermes Stands With Analysts
June 07, 2023
Via
Benzinga
Alkermes Raises FY23 Outlook Following Arbitration Award from Janssen Agreements
June 06, 2023
Via
Benzinga
Sarissa Urges Alkermes Shareholders to Vote the Universal Blue Card to Upgrade Alkermes for the Benefit of Shareholders
June 05, 2023
From
Sarissa Capital Management LP
Via
Business Wire
Alkermes Earnings Perspective: Return On Capital Employed
April 27, 2023
Via
Benzinga
Analyst Expectations for Alkermes's Future
April 27, 2023
Via
Benzinga
The Latest Analyst Ratings for Alkermes
April 27, 2023
Via
Benzinga
A Preview Of Alkermes's Earnings
April 25, 2023
Via
Benzinga
Alkermes Stock Sees Rising Relative Strength Rating
March 28, 2023
The Relative Strength (RS) Rating for Alkermes stock climbed into a new percentile Tuesday, as it got a lift from 69 to 77.
Via
Investor's Business Daily
Earnings Scheduled For February 16, 2023
February 16, 2023
Companies Reporting Before The Bell • RELX (NYSE:RELX) is estimated to report earnings for its Fiscal Year 2022. • Coca-Cola Europacific (NASDAQ:CCEP) is expected to report earnings for its Fiscal Year...
Via
Benzinga
Alkermes Earnings Preview
February 15, 2023
Via
Benzinga
Analyst Ratings for Alkermes
December 06, 2022
Via
Benzinga
Alkermes Plans Separating Its Oncology Unit; Lifts FY22 Earnings Guidance
November 02, 2022
Via
Benzinga
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector
March 15, 2023
To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy.
Via
InvestorPlace
Alkermes: Commercialization Program On Track, Sales Coming In Strong
March 04, 2023
The bigger biotechs have done a good job lately, with solid earnings to date. Speaking of which, Alkermes plc has recently exceeded estimates. Let's take a closer look at the company's performance.
Via
Talk Markets
Alkermes Stock Sees Rising Relative Price Strength
February 17, 2023
The Relative Strength (RS) Rating for Alkermes stock entered a new percentile Friday, with an increase from 79 to 86.
Via
Investor's Business Daily
Seattle Genetics' 'Refreshing' Enthusiasm Drives Stock Surge; Alkermes Briefly Breaks Out
February 16, 2023
Seattle Genetics' guidance deliberately excludes a looming opportunity for Padcev.
Via
Investor's Business Daily
Alkermes's Return On Capital Employed Insights
November 10, 2022
Benzinga Pro data, Alkermes (NASDAQ:ALKS) reported Q3 sales of $252.36 million. Earnings fell to a loss of $63.97 million, resulting in a 112.28% decrease from last quarter.
Via
Benzinga
Recap: Alkermes Q2 Earnings
July 27, 2022
Alkermes (NASDAQ:ALKS) reported its Q2 earnings results on Wednesday, July 27, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 3, 2022
November 03, 2022
Upgrades
Via
Benzinga
Recap: Alkermes Q3 Earnings
November 02, 2022
Alkermes (NASDAQ:ALKS) reported its Q3 earnings results on Wednesday, November 2, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings Alkermes missed estimated...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 14, 2022
October 14, 2022
Upgrades
Via
Benzinga
Domino's Pizza To Rally 20%? Here Are 5 Other Price Target Changes For Friday
October 14, 2022
Wedbush raised Domino's Pizza, Inc. (NYSE: DPZ) price target from $370 to $400. Wedbush analyst Nick Setyan maintained an Outperform rating on the stock. Domino's shares rose 10.4% to close at $333.26...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 16, 2022
August 16, 2022
Via
Benzinga
Looking Into Alkermes's Return On Capital Employed
July 28, 2022
According to data from Benzinga Pro, during Q2, Alkermes's (NASDAQ:ALKS) reported sales totaled $276.22 million. Despite a 16.06% increase in earnings, the company posted a loss of $30.14 million.
Via
Benzinga
Daily Biotech Pulse: Teva's Opioids Settlement, Criminal Investigation Against Cassava, Durable Responses For IN8bio's Leukemia Therapy
July 27, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Earnings Preview: Alkermes
July 26, 2022
Alkermes (NASDAQ:ALKS) is set to give its latest quarterly earnings report on Wednesday, 2022-07-27. Here's what investors need to know before the announcement. Analysts estimate that Alkermes will...
Via
Benzinga
Biotech Hasn't Been This Blazing Hot Since Early 2021 — Here Are The Top 5
July 15, 2022
The group has several commonalities, including strong ratings and promising charts.
Via
Investor's Business Daily
Sarissa Capital Comments on Alkermes Annual Meeting
July 06, 2022
From
Sarissa Capital Management LP
Via
Business Wire
Northrop Grumman Leads 5 Defensive Plays Near Buy Points
July 02, 2022
Northrop headlines 5 stocks near buy points with the mettle to withstand a recession.
Via
Investor's Business Daily
Day One Biopharmaceuticals Stock Scores Rising Relative Strength Upgrade
June 15, 2022
Day One Biopharmaceuticals stock, which saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, rising from 83 to 92.
Via
Investor's Business Daily
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.